Literature DB >> 17015178

Reduced nonprotein thiols inhibit activation and function of MMP-9: implications for chemoprevention.

Ping Pei1, Michael P Horan, Russ Hille, Craig F Hemann, Steven P Schwendeman, Susan R Mallery.   

Abstract

Clinical studies demonstrate a positive correlation between the extent of matrix metalloproteinase (MMP) activation and malignant progression of precancerous lesions. Therefore, identification of effective, well-tolerated MMP inhibitors represents a rational chemopreventive strategy. A variety of agents, including proteinases and thiol-oxidizing compounds, activate MMPs by initiating release of the propeptide's cysteine sulfur "blockage" of the MMP active site. Despite the importance of the propeptide's cysteine thiol in preserving MMP latency, limited studies have evaluated the effects of reduced thiols on MMP function. This study investigated the effects of two naturally occurring nonprotein thiols, i.e., glutathione (GSH) and N-acetylcysteine (NAC), on activation, function, and cellular-extracellular matrix interactions of the basement-membrane-degrading gelatinase, MMP-9. Our results reveal that NAC and GSH employ protein S-thiolation to inhibit organomercurial activation of pro-MMP-9. Gelatinase activity assays showed that GSH and NAC significantly inhibited MMP-9 but not MMP-2 function, implying isoform structural specificity. Immunoblot analyses, which suggested GSH interacts with MMP-9's active-site Zn, were corroborated by computational molecular modeling. Cell invasion assays revealed that NAC enhanced endostatin's ability to inhibit human cancer cell invasion. Collectively, these data demonstrate that nonprotein thiols suppress MMP-9 activation and function and introduce the prospect for their use in chemopreventive applications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17015178      PMCID: PMC2405910          DOI: 10.1016/j.freeradbiomed.2006.07.014

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  42 in total

1.  Structural characterization of the catalytic active site in the latent and active natural gelatinase B from human neutrophils.

Authors:  O Kleifeld; P E Van den Steen; A Frenkel; F Cheng; H L Jiang; G Opdenakker; I Sagi
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

2.  Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine.

Authors:  A Albini; M Morini; F D'Agostini; N Ferrari; F Campelli; G Arena; D M Noonan; C Pesce; S De Flora
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

Review 3.  Matrix metalloproteinases in tumour invasion and metastasis.

Authors:  S Curran; G I Murray
Journal:  J Pathol       Date:  1999-11       Impact factor: 7.996

4.  Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation.

Authors:  T Okamoto; T Akaike; T Sawa; Y Miyamoto; A van der Vliet; H Maeda
Journal:  J Biol Chem       Date:  2001-06-06       Impact factor: 5.157

5.  Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model.

Authors:  S R Mallery; A Shenderova; P Pei; S Begum; J R Ciminieri; R F Wilson; B C Casto; D E Schuller; M A Morse
Journal:  Anticancer Res       Date:  2001 May-Jun       Impact factor: 2.480

Review 6.  Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems.

Authors:  Steven P Schwendeman
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2002       Impact factor: 4.889

7.  Sustained angiogenesis enables in vivo transplantation of mucocutaneous derived AIDS-related Kaposi's sarcoma cells in murine hosts.

Authors:  S R Mallery; P Pei; J Kang; G Zhu; G M Ness; S P Schwendeman
Journal:  Carcinogenesis       Date:  2000-09       Impact factor: 4.944

8.  Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.

Authors:  Mary Cianfrocca; Timothy P Cooley; Jeannette Y Lee; Michelle A Rudek; David T Scadden; Lee Ratner; James M Pluda; William D Figg; Susan E Krown; Bruce J Dezube
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

Review 9.  Angiogenesis: regulators and clinical applications.

Authors:  S Liekens; E De Clercq; J Neyts
Journal:  Biochem Pharmacol       Date:  2001-02-01       Impact factor: 5.858

10.  Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor.

Authors:  Siân Rowsell; Paul Hawtin; Claire A Minshull; Holly Jepson; Sarah M V Brockbank; Derek G Barratt; Anthony M Slater; William L McPheat; David Waterson; Adriano M Henney; Richard A Pauptit
Journal:  J Mol Biol       Date:  2002-05-24       Impact factor: 5.469

View more
  10 in total

1.  Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF.

Authors:  Meng Tong; Brandon Lloyd; Ping Pei; Susan R Mallery
Journal:  J Cell Biochem       Date:  2008-12-01       Impact factor: 4.429

2.  Redox-active magnetic resonance imaging contrast agents: studies with thiol-bearing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid derivatives.

Authors:  Bhumasamudram Jagadish; Gerald P Guntle; Dezheng Zhao; Vijay Gokhale; Tarik J Ozumerzifon; Ali M Ahad; Eugene A Mash; Natarajan Raghunand
Journal:  J Med Chem       Date:  2012-11-28       Impact factor: 7.446

Review 3.  The impact of redox and thiol status on the bone marrow: Pharmacological intervention strategies.

Authors:  Christina L Grek; Danyelle M Townsend; Kenneth D Tew
Journal:  Pharmacol Ther       Date:  2010-10-15       Impact factor: 12.310

4.  Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium.

Authors:  Gerald P Guntle; Bhumasamudram Jagadish; Eugene A Mash; Garth Powis; Robert T Dorr; Natarajan Raghunand
Journal:  Transl Oncol       Date:  2012-06-01       Impact factor: 4.243

5.  Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.

Authors:  Kashappa Goud H Desai; Susan R Mallery; Steven P Schwendeman
Journal:  Pharm Res       Date:  2007-09-22       Impact factor: 4.200

Review 6.  Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia.

Authors:  E Candelario-Jalil; Y Yang; G A Rosenberg
Journal:  Neuroscience       Date:  2008-06-19       Impact factor: 3.590

7.  The effects of reactive species on the tumorigenic phenotype of human head and neck squamous cell carcinoma (HNSCC) cells.

Authors:  Jennifer E Bradburn; Ping Pei; Laura A Kresty; James C Lang; Allan J Yates; Adam P McCormick; Susan R Mallery
Journal:  Anticancer Res       Date:  2007 Nov-Dec       Impact factor: 2.480

8.  Exogenous coenzyme Q10 modulates MMP-2 activity in MCF-7 cell line as a breast cancer cellular model.

Authors:  Massih Bahar; Shahnaz Khaghani; Parvin Pasalar; Maliheh Paknejad; Mohammad Reza Khorramizadeh; Hossein Mirmiranpour; Siavash Gerayesh Nejad
Journal:  Nutr J       Date:  2010-11-30       Impact factor: 3.271

Review 9.  Glutamate Transport: A New Bench to Bedside Mechanism for Treating Drug Abuse.

Authors:  Sade Spencer; Peter W Kalivas
Journal:  Int J Neuropsychopharmacol       Date:  2017-10-01       Impact factor: 5.176

10.  Curcumin Oxidation Is Required for Inhibition of Helicobacter pylori Growth, Translocation and Phosphorylation of Cag A.

Authors:  Ashwini Kumar Ray; Paula B Luis; Surabhi Kirti Mishra; Daniel P Barry; Mohammad Asim; Achyut Pandey; Maya Chaturvedi; Jyoti Gupta; Shilpi Gupta; Shweta Mahant; Rajashree Das; Pramod Kumar; Keith T Wilson; Claus Schneider; Rupesh Chaturvedi
Journal:  Front Cell Infect Microbiol       Date:  2021-12-24       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.